Fig. 5

In vivo antitumor activity against 4T1 breast xenograft tumors (n = 5). a Illustration of the treatment schedule for HSP inhibition-potentiated PTT; b Tumor growth profiles; c Tumor % of body weight; d Western blotting results of HSP90 expression in tumor tissues; e Body weight changes of BALB/c mice bearing 4T1 tumors after injected with different formulations. n.s. = no significance, * P < 0.05, **** P < 0.0001